We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AKI Biomarker Described for Pediatric Malaria

By LabMedica International staff writers
Posted on 28 Feb 2018
Acute kidney injury (AKI) is an important complication in severe malaria that is associated with increased mortality in both pediatric and adult populations. However, until recently, the incidence of AKI in pediatric malaria was under-appreciated as few children develop signs of overt renal failure and creatinine testing is not routinely available in resource-constrained settings.

Chitinase-3-like 1 protein (CHI3L1) is a secreted glycoprotein produced by a variety of cell types in response to inflammation, including activated macrophages, neutrophils, and fibroblasts. CHI3L1 is highly expressed in healthy kidney tissue and is freely filtered by the glomerulus. CHI3L1 is also secreted by activated macrophages in the kidney upon stress or damage.

Infectious disease specialists working with their colleagues at the University of Toronto (Toronto, ON, Canada) conducted a study of children in Uganda between 2011 and 2013. Inclusion criteria were age 1–10 years, Plasmodium falciparum by rapid diagnostic test (RDT); using the First Response Malaria Ag. HRP2/pLDH Combo Rapid Diagnostic Test and selected severe malaria criteria.

The team assessed creatinine and blood urea nitrogen (BUN) at the point of care using i-STAT CHEM8+ or Crea cartridges plasma samples were collected daily from children during hospitalization (day 1–4), and at follow up (day 14) and stored at − 80 °C until testing. Cystatin C and CHI3L1 were measured by enzyme-linked immunosorbent assay (ELISA). Markers of intravascular hemolysis, endothelial activation and inflammation were measured by ELISA.

The team found that CHI3L1 levels were elevated in patients with AKI and remained higher over hospitalization and admission and CHI3L1 levels were elevated in children who died. A one unit increase in log10 (CHI3L1) was associated with a 4.1-fold increased risk of in-hospital death and a one unit increase in log10 (CHI3L1) was associated with a 3.21-fold increased risk of death by six months. To explore potential pathophysiologic mechanisms linking elevated CHI3L1 and mortality in severe pediatric malaria, admission levels of CHI3L1 were compared with other host markers of immune and endothelial activation. CHI3L1 was correlated with pathways implicated in the pathobiology of severe malaria including markers of endothelial activation.

The authors concluded that CHI3L1 is a novel biomarker of malaria-associated AKI and an independent risk factor for mortality that is associated with well-established pathways of severe malaria pathogenesis including inflammation, endothelial activation, and hemolysis. The study was published on February 15, 2018, in the Malaria Journal.

Related Links:
University of Toronto


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Centromere B Assay
Centromere B Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.